Filenews 1 July 2022
In order to better serve the beneficiaries, the Health Insurance Organization informs the beneficiaries that the prescription criteria for the pharmaceutical products Xarelto, Eliquis and Pradaxa have been expanded. Therefore, a larger number of beneficiaries will be able to receive the above pharmaceutical products through the GHS.
Beneficiaries affected by this decision are kindly requested to contact their treating physician in order to be informed whether they meet the new criteria that have been put in place by the Organization.
